EFFICACY AND SAFETY OF SARILUMAB VERSUS ADALIMUMAB IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MONOTHERAPY STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INTOLERANCE OR INADEQUATE RESPONSE TO METHOTREXATE

被引：0
|
作者：
Burmester, G. [1 ,2 ,3 ]
Lin, Y. [4 ]
Mangan, E. [5 ]
Van Hoogstraten, H. [4 ]
Vargas, J. [6 ]
Lee, E. [7 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Free Univ, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Sanofi Genzyme, Bridgewater, MA USA
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Quantum Res, Puerto Varas, Chile
[7] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
INTERNAL MEDICINE JOURNAL | 2017年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P53
引用
收藏
页码：26 / 26
页数：1
相关论文
共 50 条
  • [31] Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
    Tanaka, Yoshiya
    Wada, Kazuteru
    Takahashi, Yoshinori
    Hagino, Owen
    van Hoogstraten, Hubert
    Graham, Neil M. H.
    Kameda, Hideto
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [32] Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
    Yoshiya Tanaka
    Kazuteru Wada
    Yoshinori Takahashi
    Owen Hagino
    Hubert van Hoogstraten
    Neil M. H. Graham
    Hideto Kameda
    Arthritis Research & Therapy, 21
  • [33] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
    Strand, Vibeke
    Gossec, Laure
    Proudfoot, Clare W. J.
    Chen, Chieh-I
    Reaney, Matthew
    Guillonneau, Sophie
    Kimura, Toshio
    van Adelsberg, Janet
    Lin, Yong
    Mangan, Erin K.
    van Hoogstraten, Hubert
    Burmester, Gerd R.
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [34] Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
    Vibeke Strand
    Laure Gossec
    Clare W. J. Proudfoot
    Chieh-I Chen
    Matthew Reaney
    Sophie Guillonneau
    Toshio Kimura
    Janet van Adelsberg
    Yong Lin
    Erin K. Mangan
    Hubert van Hoogstraten
    Gerd R. Burmester
    Arthritis Research & Therapy, 20
  • [35] UPADACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF A SELECTIVE JAK1 INHIBITOR
    Genovese, M. C.
    Fleischmann, R.
    Combe, B.
    Hall, S.
    Zhang, Y.
    Zhou, Y.
    Mohamed, M. F.
    Meerwein, S.
    Pangan, A. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 970 - 970
  • [36] Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
    Fleischmann, Roy
    Mysler, Eduardo
    Hall, Stephen
    Kivitz, Alan J.
    Moots, Robert J.
    Luo, Zhen
    DeMasi, Ryan
    Soma, Koshika
    Zhang, Richard
    Takiya, Liza
    Tatulych, Svitlana
    Mojcik, Christopher
    Krishnaswami, Sriram
    Menon, Sujatha
    Smolen, Josef S.
    LANCET, 2017, 390 (10093): : 457 - 468
  • [37] EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSIONOF A PHASE III MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    Burrnester, Gerd R.
    Fiore, Stefano
    Hu, Chih-Chi
    Fay, Jon
    Lee, Eun Bong
    Genovese, Mark C.
    RHEUMATOLOGY, 2018, 57
  • [38] A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
    Kavanaugh, Arthur
    Decktor, Dennis L.
    Fan, Chunpeng
    van Adelsberg, Janet
    Martincova, Renata
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1233 - S1234
  • [39] EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
    Rubbert-Roth, A.
    Enejosa, J.
    Pangan, A.
    Xavier, R.
    Haraoui, B.
    Rischmueller, M.
    Khan, N.
    Zhang, Y.
    Martin, N.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1011 - 1012
  • [40] EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Barcomb, L.
    Lu, W.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1315 - 1316
12345